Mixed dyslipidemias in primary care patients in France
Vascular Health and Risk Management, 04/25/2012
Laforest L et al. – At least one dyslipidemia persisted in half of all patients and two–thirds of high cardiovascular risk patients treated with a statin. Dyslipidemias of high density lipoprotein cholesterol (HDL–C) and/or triglycerides were as prevalent as elevated low density lipoprotein cholesterol (LDL–C) among high cardiovascular risk patients.
This is a prospective, observational, cross–sectional, pharmacoepidemiologic study with a total of 2544 consecutive patients treated with a statin for at least 6 months.
Prevalence of isolated and mixed dyslipidemias of low density lipoprotein cholesterol (LDL–C), high density lipoprotein cholesterol (HDL–C), and triglycerides among all patients and among patients at high cardiovascular risk; clinical variables associated with attainment of lipid targets/normal levels in French national guidelines.
At least one dyslipidemia was present in 50.8% of all patients and in 71.1% of high–risk patients.
Dyslipidemias of LDL–C, HDL–C, and triglycerides were present in 27.7%, 12.4%, and 28.7% of all patients, respectively, and in 51.0%, 18.2%, and 32.5% of high–risk patients, respectively.
Among all subjects with any dyslipidemia, 30.9% had mixed dyslipidemias and 69.4% had low HDL–C and/or elevated triglycerides, while 30.6% had isolated elevated LDL–C; corresponding values for high–risk patients were 36.8%, 58.9%, and 41.1%.
Age, gender, body mass index and Framingham Risk Score >20% were the factors significantly associated with attainment of normal levels for ≥2 lipid levels.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.